Hans-Jochem Kolb
Overview
Explore the profile of Hans-Jochem Kolb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill W, Sotlar K, Hautmann A, Kolb H, Ullmann J, Hausmann A, et al.
Eur J Haematol
. 2024 Jan;
112(5):819-831.
PMID: 38243840
Objectives: To describe late transplant-associated thrombotic microangiopathy (TA-TMA) as chronic endothelial complication in bone marrow (BM) after allogeneic hematopoietic stem cell transplantation (HSCT). Methods: BM specimens along with conventional diagnostic...
2.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al.
Leukemia
. 2020 Sep;
34(10):2823.
PMID: 32913312
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
3.
Kolb H, Schmid C
Ann Hematol
. 2020 Jun;
99(9):1979-1988.
PMID: 32594216
The FLAMSA reduced intensity (RIC) concept, also known as "sequential therapy", is a conceptual platform for the treatment of leukemia separated in several parts: induction therapy, a sequence of antileukemic...
4.
Steger B, Floro L, Amberger D, Kroell T, Tischer J, Kolb H, et al.
J Immunother
. 2020 Jun;
43(6):204-215.
PMID: 32502139
Several tumor-associated antigens (TAAs) were recently identified, that could qualify as targets for immunotherapy, they could qualify (on RNA-level) for monitoring of tumor load. Here, we studied the expression levels...
5.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al.
Leukemia
. 2020 May;
34(8):2074-2086.
PMID: 32382082
Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change...
6.
Cominal J, da Costa Cacemiro M, Pinto-Simoes B, Kolb H, Malmegrim K, Attie de Castro F
Stem Cells Int
. 2019 Jul;
2019:6854080.
PMID: 31281380
Homoeostasis of bone marrow microenvironment depends on a precise balance between cell proliferation and death, which is supported by the cellular-extracellular matrix crosstalk. Multipotent mesenchymal stromal cells (MSC) are the...
7.
Hirn Lopez A, Deen D, Fischer Z, Rabe A, Ansprenger C, Stein K, et al.
J Immunother
. 2019 May;
42(5):143-161.
PMID: 31090655
Strategies to stabilize remissions by specific elimination of residual acute myeloid leukemia (AML) blasts are needed. Leukemia-derived dendritic cell (DCleu/DC) generated from myeloid blasts improve antileukemic T-cell reactivity and install...
8.
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, et al.
Haematologica
. 2018 Dec;
104(5):955-962.
PMID: 30514803
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg ('high-dose') imatinib accelerated achievement...
9.
Engel N, Rovo A, Badoglio M, Labopin M, Basak G, Beguin Y, et al.
Leukemia
. 2018 Jul;
33(2):508-517.
PMID: 30050122
Donor cell leukaemia (DCL) is a rare complication of allogeneic haematopoietic cell transplantation (HCT). We have investigated the prevalence and outcome of donor cell haematology malignancies within centres registered with...
10.
Norden J, Pearce K, Irving J, Collin M, Wang X, Wolff D, et al.
Int J Immunogenet
. 2018 Jul;
PMID: 30043490
Haematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological malignancies, however, the mortality rate remains high. Complications after HSCT include relapse, graft versus host disease (GvHD), graft...